Literature DB >> 15618207

Detection of gliotoxin in experimental and human aspergillosis.

Russell E Lewis1, Nathan P Wiederhold, Jingduan Chi, Xiang Y Han, Krishna V Komanduri, Dimitrios P Kontoyiannis, Randall A Prince.   

Abstract

Gliotoxin was measured in the lungs (mean, 3,976 +/- 1,662 ng/g of tissue) and sera (mean, 36.5 +/- 30.28 ng/ml) of mice with experimentally induced invasive aspergillosis (IA), and levels decreased with antifungal therapy. Gliotoxin could also be detected in the sera of cancer patients with documented (proven or probable) IA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618207      PMCID: PMC538950          DOI: 10.1128/IAI.73.1.635-637.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

Review 2.  Putative virulence factors of Aspergillus fumigatus.

Authors:  J F Tomee; H F Kauffman
Journal:  Clin Exp Allergy       Date:  2000-04       Impact factor: 5.018

3.  Natural occurrence of gliotoxin in turkeys infected with Aspergillus fumigatus, Fresenius.

Authors:  J L Richard; T J Dvorak; P F Ross
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

4.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

5.  Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen Aspergillus fumigatus.

Authors:  Emer P Reeves; Thomas Murphy; Paul Daly; Kevin Kavanagh
Journal:  J Med Microbiol       Date:  2004-08       Impact factor: 2.472

6.  Identification of an agent in cultures of Aspergillus fumigatus displaying anti-phagocytic and immunomodulating activity in vitro.

Authors:  A Müllbacher; P Waring; R D Eichner
Journal:  J Gen Microbiol       Date:  1985-05

7.  Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus.

Authors:  Harrys A Torres; Gustavo A Rivero; Russell E Lewis; Ray Hachem; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Diagn Microbiol Infect Dis       Date:  2003-05       Impact factor: 2.803

8.  The mycotoxins citrinin, gliotoxin, and patulin affect interferon-gamma rather than interleukin-4 production in human blood cells.

Authors:  G Wichmann; O Herbarth; I Lehmann
Journal:  Environ Toxicol       Date:  2002       Impact factor: 4.119

9.  Fungal metabolite gliotoxin inhibits assembly of the human respiratory burst NADPH oxidase.

Authors:  Shohko Tsunawaki; Lucia S Yoshida; Satoshi Nishida; Toshihiro Kobayashi; Takashi Shimoyama
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

10.  Immunosuppression in vitro by a metabolite of a human pathogenic fungus.

Authors:  A Müllbacher; R D Eichner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

View more
  54 in total

1.  LaeA, a regulator of morphogenetic fungal virulence factors.

Authors:  Jin Woo Bok; S Arunmozhi Balajee; Kieren A Marr; David Andes; Kristian Fog Nielsen; Jens C Frisvad; Nancy P Keller
Journal:  Eukaryot Cell       Date:  2005-09

2.  Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production.

Authors:  Robert A Cramer; Michael P Gamcsik; Rhea M Brooking; Laura K Najvar; William R Kirkpatrick; Thomas F Patterson; Carl J Balibar; John R Graybill; John R Perfect; Soman N Abraham; William J Steinbach
Journal:  Eukaryot Cell       Date:  2006-06

Review 3.  Aspergillus fumigatus: principles of pathogenesis and host defense.

Authors:  Tobias M Hohl; Marta Feldmesser
Journal:  Eukaryot Cell       Date:  2007-09-21

4.  Mycotoxins in indoor environments.

Authors:  H M Ammann
Journal:  Mycotoxin Res       Date:  2005-09       Impact factor: 3.833

5.  A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus.

Authors:  Zaida G Ramirez-Ortiz; Chrono K Lee; Jennifer P Wang; Louis Boon; Charles A Specht; Stuart M Levitz
Journal:  Cell Host Microbe       Date:  2011-05-19       Impact factor: 21.023

6.  Identification of cryptic products of the gliotoxin gene cluster using NMR-based comparative metabolomics and a model for gliotoxin biosynthesis.

Authors:  Ry R Forseth; Ellen M Fox; DaWoon Chung; Barbara J Howlett; Nancy P Keller; Frank C Schroeder
Journal:  J Am Chem Soc       Date:  2011-06-06       Impact factor: 15.419

Review 7.  Aspergillus fumigatus: virulence genes in a street-smart mold.

Authors:  David S Askew
Journal:  Curr Opin Microbiol       Date:  2008-06-23       Impact factor: 7.934

8.  Gliotoxin in Aspergillus fumigatus: an example that mycotoxins are potential virulence factors.

Authors:  Herbert Hof; Claudio Kupfahl
Journal:  Mycotoxin Res       Date:  2009-08-11       Impact factor: 3.833

9.  Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites.

Authors:  Ronen Ben-Ami; Russell E Lewis; Konstantinos Leventakos; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

10.  Genomewide screening for genes associated with gliotoxin resistance and sensitivity in Saccharomyces cerevisiae.

Authors:  Georgios Chamilos; Russell E Lewis; Gregory A Lamaris; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.